Cargando…
A pH-Responsive Charge-Reversal Drug Delivery System with Tumor-Specific Drug Release and ROS Generation for Cancer Therapy
INTRODUCTION: Poor cell uptake and incomplete intracellular drug release are the two major challenges for polymeric prodrug-based drug delivery systems (PPDDSs) in cancer treatment. METHODS: Herein, a PPDDS with pH-induced surface charge-reversal and reactive oxygen species (ROS) amplification for R...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955620/ https://www.ncbi.nlm.nih.gov/pubmed/32021165 http://dx.doi.org/10.2147/IJN.S230237 |
_version_ | 1783486970801946624 |
---|---|
author | Xu, Chen Song, Rijin Lu, Pei Chen, Jianchun Zhou, Yongqiang Shen, Gang Jiang, Minjun Zhang, Wei |
author_facet | Xu, Chen Song, Rijin Lu, Pei Chen, Jianchun Zhou, Yongqiang Shen, Gang Jiang, Minjun Zhang, Wei |
author_sort | Xu, Chen |
collection | PubMed |
description | INTRODUCTION: Poor cell uptake and incomplete intracellular drug release are the two major challenges for polymeric prodrug-based drug delivery systems (PPDDSs) in cancer treatment. METHODS: Herein, a PPDDS with pH-induced surface charge-reversal and reactive oxygen species (ROS) amplification for ROS-triggered self-accelerating drug release was developed, which was formed by encapsulating a ROS generation agent (vitamin K3 (VK3)) in pH/ROS dual-sensitive polymetric prodrug (PEG-b-P(LL-g-TK-PTX)-(LL-g-DMA)) based micelle nanoparticles (denoted as PVD-NPs). RESULTS: The surface charge of the PVD-NPs can change from negative to positive for enhanced cell uptake in response to tumor extracellular acidity pH. After internalization by cancer cells, PVD-NPs demonstrate dual drug release in response to intracellular ROS-rich conditions. In addition, the released VK3 can produce ROS under the catalysis by NAD(P)H:quinone oxidoreductase-1, which facilitates tumor-specific ROS amplification and drug release selectively in cancer cells to enhance chemotherapy. CONCLUSION: Both in vitro and in vivo experiments demonstrated that the PVD-NPs showed significant antitumor activity in human prostate cancer. |
format | Online Article Text |
id | pubmed-6955620 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-69556202020-02-04 A pH-Responsive Charge-Reversal Drug Delivery System with Tumor-Specific Drug Release and ROS Generation for Cancer Therapy Xu, Chen Song, Rijin Lu, Pei Chen, Jianchun Zhou, Yongqiang Shen, Gang Jiang, Minjun Zhang, Wei Int J Nanomedicine Original Research INTRODUCTION: Poor cell uptake and incomplete intracellular drug release are the two major challenges for polymeric prodrug-based drug delivery systems (PPDDSs) in cancer treatment. METHODS: Herein, a PPDDS with pH-induced surface charge-reversal and reactive oxygen species (ROS) amplification for ROS-triggered self-accelerating drug release was developed, which was formed by encapsulating a ROS generation agent (vitamin K3 (VK3)) in pH/ROS dual-sensitive polymetric prodrug (PEG-b-P(LL-g-TK-PTX)-(LL-g-DMA)) based micelle nanoparticles (denoted as PVD-NPs). RESULTS: The surface charge of the PVD-NPs can change from negative to positive for enhanced cell uptake in response to tumor extracellular acidity pH. After internalization by cancer cells, PVD-NPs demonstrate dual drug release in response to intracellular ROS-rich conditions. In addition, the released VK3 can produce ROS under the catalysis by NAD(P)H:quinone oxidoreductase-1, which facilitates tumor-specific ROS amplification and drug release selectively in cancer cells to enhance chemotherapy. CONCLUSION: Both in vitro and in vivo experiments demonstrated that the PVD-NPs showed significant antitumor activity in human prostate cancer. Dove 2020-01-08 /pmc/articles/PMC6955620/ /pubmed/32021165 http://dx.doi.org/10.2147/IJN.S230237 Text en © 2020 Xu et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Xu, Chen Song, Rijin Lu, Pei Chen, Jianchun Zhou, Yongqiang Shen, Gang Jiang, Minjun Zhang, Wei A pH-Responsive Charge-Reversal Drug Delivery System with Tumor-Specific Drug Release and ROS Generation for Cancer Therapy |
title | A pH-Responsive Charge-Reversal Drug Delivery System with Tumor-Specific Drug Release and ROS Generation for Cancer Therapy |
title_full | A pH-Responsive Charge-Reversal Drug Delivery System with Tumor-Specific Drug Release and ROS Generation for Cancer Therapy |
title_fullStr | A pH-Responsive Charge-Reversal Drug Delivery System with Tumor-Specific Drug Release and ROS Generation for Cancer Therapy |
title_full_unstemmed | A pH-Responsive Charge-Reversal Drug Delivery System with Tumor-Specific Drug Release and ROS Generation for Cancer Therapy |
title_short | A pH-Responsive Charge-Reversal Drug Delivery System with Tumor-Specific Drug Release and ROS Generation for Cancer Therapy |
title_sort | ph-responsive charge-reversal drug delivery system with tumor-specific drug release and ros generation for cancer therapy |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955620/ https://www.ncbi.nlm.nih.gov/pubmed/32021165 http://dx.doi.org/10.2147/IJN.S230237 |
work_keys_str_mv | AT xuchen aphresponsivechargereversaldrugdeliverysystemwithtumorspecificdrugreleaseandrosgenerationforcancertherapy AT songrijin aphresponsivechargereversaldrugdeliverysystemwithtumorspecificdrugreleaseandrosgenerationforcancertherapy AT lupei aphresponsivechargereversaldrugdeliverysystemwithtumorspecificdrugreleaseandrosgenerationforcancertherapy AT chenjianchun aphresponsivechargereversaldrugdeliverysystemwithtumorspecificdrugreleaseandrosgenerationforcancertherapy AT zhouyongqiang aphresponsivechargereversaldrugdeliverysystemwithtumorspecificdrugreleaseandrosgenerationforcancertherapy AT shengang aphresponsivechargereversaldrugdeliverysystemwithtumorspecificdrugreleaseandrosgenerationforcancertherapy AT jiangminjun aphresponsivechargereversaldrugdeliverysystemwithtumorspecificdrugreleaseandrosgenerationforcancertherapy AT zhangwei aphresponsivechargereversaldrugdeliverysystemwithtumorspecificdrugreleaseandrosgenerationforcancertherapy AT xuchen phresponsivechargereversaldrugdeliverysystemwithtumorspecificdrugreleaseandrosgenerationforcancertherapy AT songrijin phresponsivechargereversaldrugdeliverysystemwithtumorspecificdrugreleaseandrosgenerationforcancertherapy AT lupei phresponsivechargereversaldrugdeliverysystemwithtumorspecificdrugreleaseandrosgenerationforcancertherapy AT chenjianchun phresponsivechargereversaldrugdeliverysystemwithtumorspecificdrugreleaseandrosgenerationforcancertherapy AT zhouyongqiang phresponsivechargereversaldrugdeliverysystemwithtumorspecificdrugreleaseandrosgenerationforcancertherapy AT shengang phresponsivechargereversaldrugdeliverysystemwithtumorspecificdrugreleaseandrosgenerationforcancertherapy AT jiangminjun phresponsivechargereversaldrugdeliverysystemwithtumorspecificdrugreleaseandrosgenerationforcancertherapy AT zhangwei phresponsivechargereversaldrugdeliverysystemwithtumorspecificdrugreleaseandrosgenerationforcancertherapy |